Parkinson’s disease (PD) and Lewy Body Dementia (LBD) are defined by accumulation of alpha-synuclein (Asyn) fibrils within Lewy bodies (LBs) and Lewy neurites (LNs). The development of a Positron Emission Tomography (PET) tracer for quantifying Asyn fibrils would improve diagnostic accuracy and provide a biomarker for disease progression. We previously described radioligand [3H]Tg-1-90B, which binds to in vitro Asyn fibrils (PDB 2N0A) via interactions with residues Y39, S42 and K44. Here, we performed molecular docking studies with Tg1-90B and PD/LBD Asyn fibrils (PDB 8A9L), which predicts interactions with residues Y39 and K43 in a structurally distinct binding site. In radioligand binding assays, Tg-1-90B has moderate to high affinity (Kd 17.5 nM) for amplified LBD fibrils (PDB 8FPT), whose protofilament fold is highly similar to PD/LBD fibrils (PBD 8A9L). Autoradiography confirmed binding of [3H]Tg-1-90B to LBs in PD brain tissue. However, Tg-1-90B also binds to amyloid-beta fibrils in Alzheimer’s disease (AD) tissue, indicating insufficient selectivity for Asyn fibrils. These results indicate that Tg-1-90B binds to Asyn fibrils in PD tissue but needs further structural optimization. Binding assays with amplified LBD fibrils and autoradiography with postmortem PD tissue can guide further development of Asyn fibril PET ligands for PD/LBD.
A previous study identified [11C]M503-1619 as a lead compound for positron emission tomography (PET) radiotracer development. The goal of the current study was to conduct a structure–activity relationship (SAR) study on M503-1619 to improve its in vitro binding affinity for alpha synuclein (aSyn), as well as to identify potential radiotracers that could be labeled with fluorine-18. The results of the SAR study identified strict SARs regarding the introduction of a fluorine into the N-aryl piperazine and benzamide moieties. The most promising compound was the corresponding 2-fluoroethyl analog of M503-1619. This compound was radiolabeled with fluorine-18, followed by in vivo PET imaging studies on non-human primate and in vitro autoradiography study. In vitro autoradiography studies in human postmortem brain sections demonstrated that 18F-labeled radiotracer has higher binding to synucleinopathies versus control brain tissues. This radiotracer displays the high initial brain uptake and rapid washout that is needed for a PET radiotracer for imaging a protein such as aSyn that has a low target density in the brain. However, the formation of brain penetrant radiolabeled metabolites prevented further evaluation of this compound. Insights from this SAR study are guiding the development of novel aSyn radioligands that avoid formation of the undesirable radiolabeled metabolite.